首页> 外文期刊>Yonsei Medical Journal >Impact of Diltiazem Alone versus Diltiazem with Nitrate on Five-Year Clinical Outcomes in Patients with Significant Coronary Artery Spasm
【24h】

Impact of Diltiazem Alone versus Diltiazem with Nitrate on Five-Year Clinical Outcomes in Patients with Significant Coronary Artery Spasm

机译:单独使用地尔硫卓与硝酸地尔硫卓对严重冠状动脉痉挛患者五年临床疗效的影响

获取原文
       

摘要

Purpose Calcium channel blockers diltiazem and nitrate have been used as selective coronary vasodilators for patients with significant coronary artery spasm (CAS). However, no study has compared the efficacy of diltiazem alone versus diltiazem with nitrate for long-term clinical outcomes in patients with CAS. Materials and Methods A total of 2741 consecutive patients without significant coronary artery disease with positive CAS by acetylcholine (Ach) provocation test between November 2004 and May 2014 were enrolled. Significant CAS was defined as a narrowing of >70% by incremental intracoronary injection of 20, 50, and 100 μg of Ach into the left coronary artery. Patients were assigned to either the diltiazem group (n=842) or the dual group (diltiazem with nitrate, n=1899) at physician discretion. To adjust for potential confounders, a propensity score matching (PSM) analysis was performed using the logistic regression model. After PSM analysis, two well-balanced groups (811 pairs, n=1622, C-statistic=0.708) were generated. Results At 5 years, there were similar incidences in primary endpoints, including mortality, myocardial infarction, revascularization, and recurrent angina requiring repeat coronary angiography between the two groups. Diltiazem alone was not an independent predictor for major adverse cardiovascular events or recurrent angina requiring repeat coronary angiography. Conclusion Despite the expected improvement of endothelial function and the relief of CAS, the combination of diltiazem and nitrate treatment was not superior to diltiazem alone in reducing mortality and cardiovascular events up to 5 years in patients with significant CAS.
机译:目的钙通道阻滞剂地尔硫卓和硝酸盐已被用作患有严重冠状动脉痉挛(CAS)的患者的选择性冠状动脉血管扩张剂。但是,尚无研究比较单独使用地尔硫卓与使用硝酸盐地尔硫卓治疗CAS患者的长期临床疗效。材料与方法收集了2004年11月至2014年5月之间连续2741例无明显冠心病且CAS阳性的乙酰胆碱(Ach)激发试验的患者。显着的CAS定义为通过向冠状动脉内向左冠状动脉内逐步注射20、50和100μgAch来缩小> 70%。根据医生的判断,将患者分为地尔硫卓组(n = 842)或双重组(地尔硫卓与硝酸盐,n = 1899)。为了适应潜在的混杂因素,使用逻辑回归模型进行了倾向得分匹配(PSM)分析。在PSM分析之后,生成了两个平衡良好的组(811对,n = 1622,C统计量= 0.708)。结果在5年时,两组的主要终点发生率相似,包括死亡率,心肌梗塞,血运重建和复发性心绞痛,两组之间需要重复进行冠状动脉造影。单独使用地尔硫卓并不是主要不良心血管事件或需要反复冠状动脉造影的复发性心绞痛的独立预测因子。结论尽管预期内皮功能会改善并且CAS缓解,但地尔硫卓和硝酸盐的联合治疗在显着CAS患者中降低死亡率和心血管事件长达5年的效果并不优于单独使用地尔硫卓。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号